Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tegafur
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Tegafur
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Magicell-NK (Natural Killer Cell) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colonic Neoplasms.
Product Name : Magicell-NK
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : AT-301
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AT-301 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza in Birds.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 29, 2012
Lead Product(s) : AT-301
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
